​Salem Partners, LLC (“Salem”) is pleased to announce a successful closed transaction on August 25th, 2021, on behalf of its client, Delta Financial, LLC (“Delta”).

Delta hired Salem to find an institutional capital partner for its equipment leasing originations, servicing, and asset management business.
​
Led and founded by two equipment leasing experts (Dave Riggleman and Adam Woodard), Delta is a specialty finance / equipment leasing company that provides financial solutions to Fortune 500 companies looking to lease mission critical equipment such as forklifts, IT infrastructure (servers, etc.), medical equipment and other corporate office, logistics, and manufacturing equipment...(read more). 

Salem Partners, LLC (“Salem”) is pleased to announce a successful, $65 million loan financing that closed on July 23rd, 2021, on behalf of a best-in-class, private equity owned, residential platform (the “Company”).

The Company hired Salem to structure a bespoke credit product against a portfolio of built, under construction, and to-be-built multifamily assets (the “Portfolio”) which will provide the Company with the necessary capital to allocate to its ground-up development pipeline...(read more)

Onconano Medicine Inc. raised around $50 million in series B financing to accelerate the momentum of its technology designed to diagnose and treat cancer with high specificity. The biotech company’s nanosensor works by reacting to low pH and illuminates cancer like a lightbulb, distinguishing cancerous tissue from healthy tissue. This is intended to make it easier for surgeons to remove cancer cells while leaving healthy, functional tissue intact.

The company’s product candidates exploit pH as a biomarker to help patients across the continuum of cancer care, from diagnosis to treatment, and have been gaining momentum in recent years. They include solid tumor therapeutics, agents for real-time image-guided surgery, as well as a platform of product candidates that activate and guide the immune system to target cancer...(read more)

OncoNano Medicine, Inc. today announced the raise of an approximate $50 million Series B financing led by the healthcare investment team at Advantech Capital, a China-based cross-border institutional investment fund. Proceeds of the financing will be used, in part, to support the Phase 3 clinical trials in the U.S. and Europe for pegsitacianine, an innovative real-time imaging agent used in intraoperative surgical resection of solid tumors, and accelerate the advancement of the company’s first therapeutic development program, ONM-501, a novel immune-therapeutic formulated with the company’s core delivery technology...(read more)

Femasys Inc., a biomedical company focused on transforming women's healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas, today announced the pricing of its initial public offering of 2,650,000 shares of its common stock at a public price of $13.00 per share. The gross proceeds to Femasys from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $34.45 million. All of the shares are being offered by Femasys. In addition, Femasys has granted the underwriters a 30-day option to purchase an additional 397,500 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions.

The shares are expected to begin trading on the Nasdaq Capital Market on June 18, 2021, under the ticker symbol “FEMY.” The offering is expected to close on June 22, 2021, subject to customary closing conditions...(read more)

Salem Partners, LLC (“Salem”) is pleased to announce a successful transaction closing on May 12th , 2021, on behalf of its client, Rainmaker Holdings Group LLC (“Rainmaker”).

​Rainmaker hired Salem to find an institutional capital partner for its growing professional athlete / sports lending business. Rainmaker is a specialty finance company that invests structured debt and equity capital in the media & entertainment, real estate, and sports sectors. Rainmaker was looking to significantly grow their lending business to NFL, NBA, MLB, and NHL athletes through a partnership with...(read more) 

Salem Partners, LLC (“Salem”) is pleased to announce a successful transaction closing on May 6th, 2021, on behalf of its client, Jupiter Land Holdings LLC (“Jupiter”).
​
Jupiter hired Salem to identify and raise $30 million in joint-venture LP equity capital (the “Venture”). After closing, the Venture will horizontally develop the raw land into both residential / for-sale lots and commercial pads (industrial) on a 52-acre land parcel in Murrieta, CA. The land site is adjacent to the prestigious Loma Linda University Medical Center, which is one of the...(read more)

​Hubbell Incorporated, (NYSE: HUBB) $8.62B, manufacturer of electronic, industrial, and utility products to solve business challenges, has acquired Armorcast Products Company (“Armorcast”). In coming together, Armorcast’s strong customer base and diverse product line helps Hubbell’s west coast expansion and entry into new market opportunities.
​
Salem Partners has enjoyed a long-standing relationship with the Boghossian family, 2nd generation owners of Armorcast...(read more)

Salem Partners, LLC (“Salem”) is pleased to announce a successful closing on behalf of its client, Geyser Holdings, LLC and its CEO, Russell Geyser (“Geyser”). Geyser hired Salem to identify and raise the required joint-venture equity capital with the objective to acquire an institutional class, creative office asset called Hollywood 959, located in the heart of the Hollywood Media District in Los Angeles, CA.

​Hollywood 959 is a recently developed, 250,000 SF class A, creative office campus developed by JH Snyder Co. Located next door to Sunset Las Palmas Studios, Hollywood 959 is... (read more)

​LOS ANGELES, CA August 10, 2020 - Erik Ridgley, CFA is CEO & chief investment officer of Salem Partners Wealth Management, a boutique multi-family investment office for founders, CEOs, entrepreneurial families, and ultra-high net worth individuals. His firm is a fiduciary and fee-only SEC-registered investment adviser (RIA) that combines institutional expertise in public markets and private investments with personalized financial planning and customized portfolios to drive successful after-tax results and build long-term client relationships. This is his fourth decade of investment management...(read more) 

 OncoNano Medicine, Inc., a biotechnology company developing ultra pH-sensitive micelles for the detection, staging and treatment of cancer, today announced two poster presentations – including a late-breaking abstract – for the Society for the Immunotherapy of Cancer (SITC) Annual Meeting to be held in National Harbor, Maryland, November 6-10. OncoNano’s core technology is a library of tunable, ultra pH-sensitive micelles that exist intact under baseline physiological pH conditions but dissociate to release their payload under different, predesignated pH levels... (read more)

OncoNano Medicine, Inc. today announced that it has been awarded $15.4 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to advance ONM-500, one of OncoNano’s innovative oncology product candidates. In ONM-500, OncoNano leverages its proprietary pH-sensitive micelle technology to deliver antigens while activating innate immunity for the treatment of cancers caused by the human papilloma virus (HPV). This grant award adds to an initial $6 million grant that the company received from CPRIT in 2014 for advancement of the company’s ONM-100, where OncoNano’s micelle technology is being used to intraoperatively image tumors during surgical resection, currently in Phase 2 clinical trials... (read more)

Salem Partners, LLC (“Salem Partners”) is pleased to announce the successful completion of a $35 million senior loan for its client, Urban Mining Company (“UMC”) and its investors and affiliates. UMC presented Salem Partners with the challenge to structure a credit product that would provide enough proceeds to refinance its existing real estate debt, finish its mission critical manufacturing facility in the Austin / San Marcos region of Texas and capitalize all transaction and interest costs (a proceeds level which was unavailable by typical bank lenders) all within a tight time frame... (read more)

LOS ANGELES, CA August 6, 2019 - Erik Ridgley, CFA is CEO & Chief Investment Officer of Salem Partners Wealth Management, a boutique multi-family investment office for founders, CEOs, entrepreneurial families, and ultra-high net worth individuals. His firm is a fiduciary and fee-only SEC-registered investment adviser that combines institutional expertise in public markets and private investments with personalized financial planning and customized portfolios to drive successful outcomes and build long-term client relationships...(read more) ​

OncoNano Medicine, Inc. today announced the completion of its Phase 1a clinical trial and expansion into Phase 1b to evaluate ONM-100, the intravenously administered imaging agent to detect tumors and metastatic lymph nodes in solid cancers during surgery. The results of Phase 1a will be included in a poster presentation at the San Antonio Breast Cancer Symposium being held on December 4-8, 2018... (read more)

​AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing vital new therapies based on a novel peptide platform, today announced that it has raised $5 million in Convertible Note funding, led by Barer & Son Capital with additional funds from Rapha Capital Management, Salem Partners, TEDCO, and Piedmont Capital Partners. In concert with the funding, AsclepiX expanded its board to add Josh Barer, Kevin Slawin, MD, and Sapna Srivastava, PhD, to the founding members Aleksander Popel, PhD and Jordan J. Green, PhD and CEO Wendy Perrow, MBA... (read more)

Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its lead product, Sebacia Microparticles. This significant achievement is a milestone in the treatment of acne and follows the company’s completion of its pivotal study, which clearly demonstrated clinical efficacy and safety of Sebacia Microparticles, and its 510(k) submission to the FDA in June 2018... (read more)

Synteract has snapped up the specialty contract researcher Cu-Tech, with plans to establish a dedicated center for the development of dermatology products and make the midsized, global CRO into a destination for skin-care clinical trials.
​
The Mountain Lakes, New Jersey-based Cu-Tech has managed more than 130 dermatology trials over the past two decades, covering a variety of indications... (read more)

Salem Partners, LLC is pleased to announce the successful completion and placement of a $54 million revolving credit facility for its client, Eisenhower Property Group (“EPG”). Salem Partners advised EPG on an exclusive basis and selected a credit hedge fund to provide the financing. First closing of the facility occurred on June 13th, 2018.

Jeff Barcy, Managing Director of Salem Partners’ real estate investment banking group, and Parker Bennett, Director of real estate investment banking, led negotiations and... (read more)

SOUTHLAKE, TX - OncoNano Medicine, Inc. today announced the closing of a $11.7 million Series A financing. The transaction was arranged by Salem Partners, who also participated as a principal investor. The Series A funding supplements a $6 million grant previously received from the Cancer Prevention and Research Institute of Texas (CPRIT). The funding will be used to support the company’s continued clinical development of a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease indications such as cancer. The company is also pleased to announce the appointment of five established industry leaders to its Board of Directors... (read more)

LOS ANGELES, CA - Salem Partners, LLC is pleased to announce the successful completion of a $40 million convertible preferred equity placement for its client, Four Springs Capital Trust (“FSCT” or “Four Springs”) with Guggenheim Investments (“Guggenheim”).  The transaction closed on January 23th, 2018, with Salem Partners acting as the financial advisor and investment bank to FSCT.  Jeff Barcy, Managing Director of Salem Partners’ real estate investment banking group, and Parker Bennett, Director of real estate investment banking, led negotiations... (read more)